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OBJECTIVES The purpose of this study was to assess the incidence of warfarin fetal complications and
whether they are dose-dependent.
BACKGROUND Gravid patients with mechanical heart valves require long-term anticoagulant therapy.
Controversy exists concerning the appropriate treatment of these patients.
METHODS Forty-three women on warfarin carrying out 58 pregnancies were studied. For each patient
with full-term pregnancy a caesarian section was scheduled for the 38th week during brief
warfarin discontinuation. Maternal and fetal complications were evaluated. Fetal complica-
tions were divided according to the warfarin dosage #5 mg and .5 mg necessary to keep an
international normalized ratio (INR) of 2.5 to 3.5, and analyzed subsequently.
RESULTS A total of 58 pregnancies were observed: 31 healthy babies (30 full term, 1 premature) and
27 fetal complications (22 spontaneous abortions, 2 warfarin embryopathies, 1 stillbirth, 1
ventricular septal defect, 1 growth retardation) were recorded. Two maternal valve throm-
boses occurred. No fetal or maternal bleeding was observed during caesarian sections or
premature vaginal delivery. Patients whose warfarin doses during pregnancy were .5 mg had
22 fetal complications, whereas those taking a dose #5 mg had only five fetal complications
(p 5 0.0001). For an increase of the warfarin dose there was a substantially increased
probability of fetal complications (p , 0.0001; r , 0.7316).
CONCLUSIONS There is a close dependency between warfarin dosage and fetal complications. Patients on
warfarin anticoagulation may be delivered by planned caesarian section at the 38th week while
briefly interrupting anticoagulation. (J Am Coll Cardiol 1999;33:1637–41) © 1999 by the
American College of Cardiology
In patients with mechanical prosthetic heart valves, long-
term anticoagulation is mandatory to prevent thromboem-
bolic phenomena. The risk of maternal thromboembolic
events is heightened during pregnancy because of the
patient’s hypercoagulable state, which is characterized by
increased levels of clotting factors and of fibrinogen and
platelet adhesiveness (1).
See page 1642
Warfarin provides effective protection against thrombo-
embolism, but its use in pregnancy is associated with an
augmented rate of abortion and the risk of warfarin-induced
embryopathy (1–3).
It has previously been shown (4,5) that the teratogenic
effect of warfarin may be prevented if this agent is discon-
tinued from before the 6th until the 12th week of preg-
nancy. Several investigators have advocated substituting
subcutaneous heparin for warfarin, either throughout the
gestation period (2,3) or during the first trimester and the
last week of pregnancy (5). In contrast, in a recent retro-
spective multicenter survey, the Working Group on Valve
Disease of the European Society of Cardiology (6–8)
concluded that heparin is neither effective nor safe for
long-term use during pregnancy in patients with mechanical
heart valves, bringing an increased risk of both thrombo-
embolism and bleeding to mother and fetus. Moreover, fetal
wastage in patients treated with heparin in the first trimester
was similar to that observed in those patients treated with
warfarin throughout the entire pregnancy (7).
Unfortunately none of these reports assessed whether the
untoward effects of warfarin on the fetus are dose-
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dependent (1–9). Oral anticoagulants have a molecular
weight of approximately 1,000 and readily cross the placenta
to the fetus. The mother may therefore be within the
therapeutic range, but the fetus is considerably overdosed
because of immature liver enzyme systems and low levels of
vitamin K–dependent clotting factors (1).
With this in mind we reviewed retrospectively our expe-
rience with pregnant women on oral anticoagulation with
the aim of assessing the incidence of fetal complications and
if these warfarin untoward effects are dose-dependent.
METHODS
Study patients. All women of childbearing age discharged
from our institution after implantation of one or more valve
prostheses were informed of the risks of pregnancy during
anticoagulation and were asked to refer to us in case of
pregnancy. From December 1987 to May 1997, 52 pregnant
women were observed in our outpatient clinic. Of these 52
patients, 9 had therapeutic abortion because of unstable
cardiac state in 3 cases and obstetric complications in 6. The
remaining 43 patients make up our study population. All 43
patients were informed again about the fetal and maternal
risks of anticoagulation with warfarin taken throughout the
entire pregnancy. All patients agreed to continue their
anticoagulation with warfarin with signed consent.
All patients were anticoagulated with sodium warfarin
throughout pregnancy keeping the same international nor-
malized ratio (INR) range of 2.5 to 3.5 they had before
pregnancy. The doses of warfarin were recorded throughout
all pregnancy, and the INR was estimated every week at our
institution. To avoid any bleeding event and/or thrombo-
embolism during delivery, caesarian section was pro-
grammed during the 38th gestational week (10). Warfarin
administration was discontinued only two days before cae-
sarian section and one day after, to be resumed after this
time to reach the same INR therapeutic range. Patients
underwent routine cardiac and obstetric examinations dur-
ing pregnancy with fetal echo carried out in the second, fifth
and eighth month.
The age of these 43 women ranged from 20 to 35 years
with a mean of 28 6 5.6 years. All patients in the study were
in New York Heart Association functional class I or II; 38
were in sinus rhythm, 4 were in atrial fibrillation and 1 had
a permanent pacemaker. Nineteen patients were taking
digitalis and diuretics during pregnancy. Before valve im-
plantation 11 women had 26 full-term pregnancies deliver-
ing 26 healthy babies. The different types of valve prostheses
used and their sites of implantation are shown in Table 1.
The valve model inserted depended on the preference of the
surgeon and reflected common usage at the time of opera-
tion. The patients’ warfarin doses before pregnancy ranged
between 3.75 and 8.75 mg.
Assessment of pregnancy outcome. Pregnancy outcome
was divided into fetal and maternal outcome. The fetal
outcome was further divided into full-term and premature
healthy babies, and fetal complications. Fetal complications
were considered spontaneous abortion, stillbirth and
warfarin-related defects. Spontaneous abortion was defined
as fetal loss before the 28th week of gestation (11). Stillbirth
was fetal death after the 28th week of gestation (11).
The maternal outcome was divided into full-term and
premature uncomplicated pregnancies, and maternal com-
plications such as valve thrombosis, thromboembolism and
bleeding.
To assess fetal complications in relation to warfarin
dosage during pregnancy, the whole population was broken
up into two groups according to the dose necessary to
maintain the INR within therapeutic range. One group
comprised patients for whom the warfarin dose was #5 mg;
in the second group the anticoagulation dose was .5 mg.
Statistical analysis. The relation between warfarin doses
and presence of fetal complications during pregnancy was
analyzed by means of one-tail Fisher exact test, checking for
association in a 2 3 2 table. Furthermore to verify if there
was a correlation between doses and complications, the
cograduation Spearman coefficient test was carried out.
RESULTS
A total of 58 pregnancies were observed in 43 patients; 43
patients had one pregnancy, 10 patients had a second
Table 1. Distribution of the Study Population According to the
Type of Prosthesis Implanted and the Valve Involved
Valve Model Mitral Aortic Mitral–Aortic Total
Starr-Edwards 8 — — 8
Lillehei-Kaster 2 — — 2
Bjork-Shiley 4 — — 4
Sorin 13 5 2 20
St. Jude 1 — 1 2
CarboMedics 3 2 2 7
Total 31 7 5 43
Table 2. Outcome of Pregnancies
Warfarin
Dose (mg)
Healthy
Fetuses
Fetal
Complications Total
#5 28 5 33
27 FT 4 SA
1 PR 1 GR
.5 3 FT 22 25
2 WE
18 SA
1 SB
1 VSD
Total 31 27 58
FT 5 full term; GR 5 growth retardation; PR 5 premature; SA 5 spontaneous
abortion; SB 5 stillbirth; VSD 5 ventricular septal defect; WE 5 warfarin
embryopathy.
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pregnancy and 5 patients a third pregnancy. Fetal outcome
divided by warfarin dose is presented in Table 2.
All the 30 full-term healthy babies were delivered by
caesarian section at the 38th week under no anticoagulation.
The mean INR value at caesarian section was 1.27 6 0.40
after two days of warfarin discontinuation. No thromboem-
bolic or bleeding complications were observed at any time
during hospitalization or in the follow-up. One patient had
a premature spontaneous vaginal delivery during the 36th
week; her INR at hospital admission was 2.6. No hemor-
rhagic complications were observed in the mother or the
healthy neonate during their hospital stay.
Fetal complications. In the group of 33 gestations, with
patients taking a warfarin dose #5 mg, there were 28
healthy babies and only five fetal complications—four spon-
taneous abortions in the first trimester of pregnancy and one
fetal growth retardation. In this group the mean dose of
warfarin, INR and INR samples were 4 6 0.8, 2.9 6 0.4
and 38 6 9, respectively.
In the other group of 25 gestations, with patients taking
a warfarin dose .5 mg, 22 fetal complications and three
full-term pregnancies were observed. In this group the mean
dose of warfarin, INR and INR samples were 7.45 6 0.9,
3 6 0.4 and 17 6 11, respectively.
In both groups the doses of warfarin during pregnancy
remained within the same range (i.e., #5 or .5 mg) as they
were before pregnancy.
There was a very strong and statistically significant
relation between warfarin dose and fetal complications (p ,
0.0001). The correlation analysis confirmed the strength of
such a relation (p , 0.0001), and indicated also that for an
increase of the warfarin dose there was a substantially
increased probability of fetal complications (r 5 0.7316).
A total of 22 spontaneous abortions were observed; 16
occurred in the first trimester of pregnancy. Of the five
abortions occurring in the second trimester, one developed
at the sixth month as a consequence of reoperation on the
mother for valve thrombosis; the fetus had no warfarin-
related malformations. Also the other four fetuses examined
after the spontaneous abortion did not present any warfarin-
related malformation. One stillbirth was recorded in the
third trimester of pregnancy; it was due to prematurity but
not to detected fetal abnormalities.
As far as warfarin embryopathy is concerned, two fetuses
spontaneously aborted at the sixth month of pregnancy,
showing typical features of warfarin embryopathy with
cartilage maldevelopment, nasal hypoplasia, depressed nasal
bridge and bifid spine. In these patients the doses of
warfarin were 6.5 and 7.5 mg, respectively.
With respect to the baby with the ventricular septal
defect, a very small muscular defect was detected echocar-
diographically. The baby was followed up by echocardiog-
raphy; eventually the defect closed in the first year of life,
and he now leads an active life.
The baby born with fetal growth retardation had no
skeletal abnormalities, mental or neurologic retardation. He
showed catch-up growth in the first year of life and he is
now fully developed.
Maternal complications. With regard to maternal compli-
cations, two cases of prosthetic valve thrombosis occurred.
One patient with a 29 Bjork-Shiley mitral valve developed
valve thrombosis at the fourth month of pregnancy. The
INR at hospital admission was 2.7, and her warfarin dose
was 3.75 mg. She had a successful emergency operation for
prosthetic valve replacement with a Sorin 29 tilting disk
valve. The baby survived the procedure and was delivered at
full term by caesarian section according to our protocol. The
other patient with a Sorin tilting disk mitral valve experi-
enced valve thrombosis at the sixth month of pregnancy.
The INR was 2.9 when she entered hospital, and her daily
dose of warfarin was 7.5 mg. She was successfully operated
on by prosthetic valve replacement with a Starr-Edwards
2M but, as reported previously, the fetus did not survive the
procedure.
No maternal embolic or bleeding events were observed in
any patient during pregnancy.
Newborn management and follow-up. All mothers were
allowed to breast-feed their infants, and no hemorrhagic
complications were observed.
All the healthy neonates were examined soon after birth
and four and 12 months later by clinical genetist, and no
signs of warfarin embryopathy were found. Mothers and
babies are reported well and free of complications at the end
of follow-up.
DISCUSSION
Outcome of pregnancy. In our study of 58 pregnancies, all
the patients were anticoagulated with warfarin throughout
pregnancy, and the fetal outcome was evaluated in relation
to the warfarin dosage.
The unique and most relevant findings of our series were
that fetal untoward effects of warfarin were dose-dependent.
Although a previous study from our center had suggested
that a warfarin dose ,5 mg is safe (10), to the best of our
knowledge, this is the first report to outline clearly the
presence of a close relation between fetal complications and
warfarin dosage. Furthermore, for an increase of warfarin
dose there is a substantially increased probability of fetal
complications. These findings were strongly supported by
statistically significant evidence. Data of patients taking
doses of warfarin ,5 mg showed that in 33 gestations, 28
healthy babies were delivered and only four spontaneous
abortions at the first trimester and one fetal growth retar-
dation occurred. On the contrary, of the 25 gestations in
patients whose warfarin intake was .5 mg, 22 fetal com-
plications and only three full-term deliveries were observed.
Our observations are supported by experimental findings.
Quick (12) and Krauss et al. (13) in pregnant dogs and
rabbits exposed to coumarin derivatives demonstrated large
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doses of the drug given up to term to be the greatest single
risk factor for fetal hemorrhage and death. Hirsh et al. (14)
confirmed this result and further suggested that an addi-
tional risk factor was the trauma of spontaneous delivery.
The explanation for these findings is that oral anticoagu-
lants have a molecular weight of approximately 1,000 and
readily cross the placenta to the fetus. The mother may
therefore be within the therapeutic range, but the fetus is
considerably overdosed because of immature liver enzyme
systems and low levels of vitamin K–dependent clotting
factors (1). Reverdiau-Moalic et al., measuring blood coag-
ulation activators and inhibitors in the healthy human fetus,
found that during intrauterine life there are low levels of
vitamin K–dependent clotting factors that steadily increase
toward birth and then toward the adult state (15). Further-
more, also the warfarin bone and cartilage teratogenesis is
very likely a dose-dependent mechanism because warfarin
blocks vitamin K regeneration by inhibiting the necessary
enzyme epoxide reductase (16). Vitamin K is an essential
cofactor for posttranslational carboxilation of glutamic acid
residues of osteocalcin and matrix Gla protein, which
modulate calcium deposition (16). A failure in the synthesis
of osteocalcin and Gla matrix protein results in chondro-
dysplasia punctata or “stippling,” and nasal hypoplasia (16).
Fetal morbidity. Among the fetal complications observed
in our series the most relevant one was spontaneous abortion
(37.9%). Most of the abortions occurred in the first three
months of pregnancy. This high abortion rate as well as its
time of occurrence are common findings in other reports
which recorded an abortion rate ranging between 16.2% and
44% (2,3,11). A similar incidence of abortion rate (37.5%)
was found by Salazar and associates in a series of patients
treated with subcutaneous heparin in the first trimester of
pregnancy (9,11). It is likely that the high abortion rate
could be explained by the placental hemorrhage, which may
occur during effective anticoagulation with either warfarin
or heparin (9). Therefore, it seems there is no advantage in
the use of heparin during the first trimester of pregnancy to
prevent fetal wastage. With regard to warfarin embryopathy,
two cases of bone maldevelopment were observed. The cases
of bone maldevelopment occurred in women in whom the
daily intake of warfarin was over 5 mg. The incidence of
embryopathy in our series was 3.4%, and this percentage is
concordant with those reported by other authors in series of
patients anticoagulated with warfarin during the entire
pregnancy (8). Although the ventricular septal defect was
included under the warfarin-induced congenital malforma-
tions, we believe that its occurrence was only coincidental,
because in large series of fetuses affected by warfarin
malformations cardiac anomalies were very rarely recorded
(1,16). Also the fetal growth retardation occurring in a baby
whose mother was on a daily dose of warfarin over 5 mg
cannot be regarded as a consequence of warfarin intake (1).
Therefore, our observations seem to confirm that among all
fetal complications, spontaneous abortion is by far the most
frequent one.
Maternal morbidity. In our series of 43 patients having 58
pregnancies, two cases of prosthetic valve thrombosis (3.4%)
were observed. Such a rate is higher than those shown in
series of nonpregnant patients with tilting disk valves (17),
indicating once again that pregnancy is a prothrombotic
state.
To reduce peripartum thromboembolic and bleeding
complications, warfarin administration was discontinued
two days before the programmed caesarian section, to be
resumed the second day after surgery.
Our peripartum antithrombotic management proved suc-
cessful, and no complications of any kind were experienced
either by mothers or by neonates. An elective caesarian
section was planned to reduce the risk of perinatal intracra-
nial hemorrhage in the fetus, although caesarian section is a
major surgery that can be associated with its own list of
morbid complications and with a substantial increase in
cost. Even when warfarin administration is stopped 10 days
before labor, the neonate could be still at risk of bleeding by
warfarin overdose (10).
Recommendations. The findings of a relevant warfarin
dose-dependent mechanism of fetal complications may
confidently suggest some clinical recommendations to apply
to the decrease of fetal and maternal complications during
pregnancy in patients taking warfarin. At the beginning of
pregnancy, those patients whose warfarin intake is #5 mg
with an INR within therapeutic range may continue to take
warfarin during the entire pregnancy under strict medical
surveillance, and consider a programmed caesarian section
at the 38th week of gestation while briefly interrupting
warfarin therapy. If the patient prefers to have vaginal
delivery, intravenous heparin over the last two weeks of
gestation should be offered as an option.
On the other hand, those patients whose warfarin doses
are .5 mg should be made fully aware of a likely much
higher risk of fetal complications during pregnancy. If they
decide to carry on pregnancy with warfarin and have a
bileaflet or an aortic valve prosthesis, the INR range may be
lowered to 2.0 to 2.5 with the aim of bringing the warfarin
intake down to 5 mg while still reaching a satisfactory
antithrombotic effect. This policy may be justified by the
observations by Sareli et al. (11) that the incidence of
thromboembolism is low in pregnant patients with newer
generation mechanical heart valves even in the presence of
low anticoagulation.
If the patient refuses to carry on warfarin anticoagulation,
heparin is the anticoagulant that has no effect on the fetus
because it does not cross the placenta (8,9). Unfortunately
long-term therapy with heparin is not safe for the mother
because of an unsatisfactory antithrombotic action and
dangerous side effects such as thrombocytopenia and osteo-
porosis (8). In those women who choose not to take
warfarin and are at high thrombotic risk (mitral prostheses,
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atrial fibrillation, first generation valves, previous thrombo-
embolism), in-hospital continuous intravenous heparin
treatment, at least between weeks 6 and 12 and two weeks
before delivery, seems justified (4). Those patients with low
thrombotic risk (aortic prostheses, sinus rhythm, newer
generation valves) may adequately be treated with subcuta-
neous heparin (4).
Low molecular weight heparin may be an attractive drug
for use during pregnancy (4), especially in patients requiring
high warfarin dosage. Similar to standard unfractioned
heparin, it does not cross the placenta, and at the same time,
it may provide additional benefits, including reduced inci-
dence of heparin-induced thrombocytopenia, osteoporosis
and bleeding complications, and no blood test is required to
monitor its safety. The drug has been used effectively and
safely to treat deep vein thrombosis during pregnancy (4),
but data in patients with a prosthetic valve are not available.
Therefore, testing low molecular weight heparin in preg-
nant women with mechanical valves may be desirable.
Because a small dose of aspirin is safe during pregnancy (4),
it may be used in addition to anticoagulation to maximize
the antithrombotic effect.
Conclusions. Although our study was carried out retro-
spectively, the conclusions are that there is a close depen-
dency between warfarin dosage and fetal complications.
Women in need of increased warfarin doses are going to
have high risk pregnancies, but whether they are going to
have an improved outcome on heparin is unknown. Above
5 mg there is an increase of fetal complications whose
frequency is still dose-dependent, but our numbers are
insufficient to show. The incidence of warfarin embryopathy
rate was not high and similar to those reported in other
series. Patients on warfarin anticoagulation may deliver by
programmed caesarian section at the 38th week while briefly
interrupting anticoagulation. This policy seems to reduce
significantly the incidence of perinatal warfarin complica-
tions, allowing pregnancy to term in those women who
maintain a stable INR within therapeutic range.
More studies are necessary to identify the best patient-
specific anticoagulant management in pregnant women with
a mechanical heart valve prosthesis. Regardless of their
anticoagulation management all pregnant patients with
mechanical heart valves should be closely monitored for
anticoagulation, and for early detection of maternal and fetal
complications during gestation.
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